Kestra Medical Technologies (KMTS) Q4 FY26 earnings call: guidance and Q&A

What are the key assumptions behind the $137 million revenue guidance for FY27, specifically regarding prescription growth, in-network mix, and revenue cycle management improvements?

Vaseem Mahboob stated that revenue growth is driven by prescription volume, in-network mix, RCM improvements, and field team expansion. He expects higher prescriptions from new accounts, deeper penetration in existing accounts, and market expansion. In-network mix is expected to be in the low to mid-80s, with continued RCM improvements. The company starts FY27 with 130 sales territories, up from 80 at the start of FY26.

“Our revenue growth has historically been driven by prescription and volume growth, in-network mix, revenue cycle management improvements and quite frankly, the growth of our field team. These KPIs are all tracking in the right direction and give us confidence in guiding to 44% growth in fiscal year 2027.”

asked by Marie Thibault · answered by Vaseem Mahboob

What are the latest thoughts on guideline recommendations and stronger support from societies following the Heart Rhythm publication citing ACE-PAS?

Brian Webster indicated that papers like this are the start of a journey towards guideline changes. The next milestone will be publishing the ACE-PAS manuscript. He highlighted the significance of the paper's insight into heart failure patients and its origin from a high-caliber physician think tank, which is positive for WCD adoption.

“I think it's going to be a journey. The papers like this are the start of that journey. We'll be publishing our manuscript for ACE-PAS soon. That will be the next milestone...”

asked by Marie Thibault · answered by Brian Webster

Kestra gained 4 points of market share last year. Is this a steady state, or can share gain accelerate in FY27 with territory expansion?

Brian Webster expects even more share gain in FY27, especially as new reps hired in FY26 become more productive. He noted that FY26 share gain didn't fully reflect the benefit of recent hiring. He also emphasized that market growth is an equally important driver.

“I would expect that we'll see even more share gain, in particular, in those territories where we were not in before adding new reps. And so as those reps come up the curve, I think we'll see that share gain start to grow.”

asked by Travis Steed · answered by Brian Webster

Why raise more money now after the equity offering, and does the new term loan structure with an M&A tranche signal increased acquisitiveness?

Vaseem Mahboob explained the financing was opportunistic to seek a lower cost of capital (24% reduction) and retain financial flexibility, not due to a need for cash. Brian Webster clarified that the M&A tranche is prospective, not for an immediate deal, but reflects interest in new technologies that leverage their direct-to-cardiology sales force.

“So we -- when we started the refinancing conversation, it was purely to go out and seek lower cost of capital... what we were able to achieve in our cost of capital was a 24% reduction from what we were paying Perceptive.”

asked by Travis Steed · answered by Vaseem Mahboob

Given market growth and Kestra's share gains, why is the FY27 revenue guidance of $137 million (44% growth) not higher?

Brian Webster stated it's not due to competitive dynamics but rather a rational management approach at the start of the fiscal year, ensuring success as new sales reps are absorbed. He reiterated that 44% growth is "pretty darn fantastic."

“I think it's us just being a rational management team. It's the start of the year. We want to make sure that as we get the year kicked off and we do absorb a lot of these new sales reps, that we set ourselves up for success.”

asked by Matthew O'Brien · answered by Brian Webster

A competitor received a warning letter from the FDA. Does this situation strengthen Kestra's position, or is it noise related to their other businesses?

Brian Webster noted that regulatory actions warrant attention. He understood the letter was directed at a different part of their competitor's business (AED and ventilator), but acknowledged that med tech companies standardize quality systems, so the competitor would likely evaluate their LifeVest business for contagion.

“My understanding of that particular situation is it was directed at a different part of their business... But my understanding right now is that, that was not directed at that particular division. It was directed at their AED and ventilator business.”

asked by Michael Polark · answered by Brian Webster

What are the key drivers behind the acceleration in revenue growth seen over the last four quarters?

Brian Webster attributed it to a combination of factors: higher in-network patient mix leading to higher revenue per fit due to insurance contracting success, increased sales territories (sales force math), and deeper penetration of existing accounts driven by clinical data and experienced sales teams.

“I think it's a combination. As we have said that we're -- we have a higher mix of in-network patients because of our insurance contracting success. And so that leads to higher revenue per fit. We have more sales territories opening up. So that's just sales force math.”

asked by Larry Biegelsen · answered by Brian Webster

What percentage of relevant territories are currently covered, and how long will it take to achieve full coverage?

Brian Webster stated that with 130 reps, Kestra has about 70% geographic coverage of the WCD prescribing universe. However, this doesn't equate to full penetration, as a single rep might cover too many accounts. He estimates achieving "full coverage" (meaning adequate rep density per account) over the next two years.

“we think that with the 130 that we landed on at the end of the year, we think that gets us somewhere around 70% of that geographic coverage. But don't mistake that for full penetration coverage... I think it's reasonable to think that over the next two years, we probably would get to a pretty good level of what we would call full coverage in the market.”

asked by David Roman · answered by Brian Webster